Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

Figure 2

Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; for test of equality over strata using Log rank test.